スプライソーム標的治療は,トリプルネガティブ乳がんにおける抗ウイルス免疫反応を誘発する.
PubMedで要約を見る
まとめ
この要約は機械生成です。Spliceosome- targeted therapies (STT) は,誤ったスプライスされたRNAをウイルスの感染を模倣させ,先天的な抗ウイルス免疫反応と腫瘍におけるアポトーシスを引き起こすことで,癌細胞死を誘発する.
科学分野
- 腫瘍学
- 分子生物学
- 免疫学
背景
- 腫瘍性因子はRNAのスプライシングを妨害し,スプライセソーム標的治療 (STT) に腫瘍を敏感にします.
- STTが誘発する癌細胞死亡の正確なメカニズムは完全に理解されていません.
研究 の 目的
- STTが癌細胞を 選択的に排除する方法を解明する
- 腫瘍細胞死と免疫反応を媒介する RNA の役割を調べる
主な方法
- MYC駆動のトリプルネガティブ乳がんモデルを使用した.
- STTに対する反応としてRNAスプライシングの異常とその下流効果を分析した.
- dsRNA結合タンパク質の相互作用と抗ウイルス信号伝達経路を研究した.
- ヒト乳がんのサンプルにおける免疫シグネチャーと相関するRNAミススプライシング.
主要な成果
- STTは,ミスをしたmRNAの細胞質蓄積を誘導し,二重鎖RNA (dsRNA) 構造を形成する.
- 内生的なdsRNAはdsRNA結合タンパク質によって認識され,抗ウイルス信号とアポトーシスを開始します.
- STTは固有の抗ウイルス信号を活性化し,免疫能力のあるモデルにおいて適応性免疫反応と腫瘍細胞死を促進します.
- ヒトの乳がん,特にMYC増幅腫瘍における免疫シグネチャーと相関する.
結論
- 誤った配列のRNAは ウイルスの模倣によって腫瘍を殺す 分子トリガーとして作用します
- dsRNAセンシング経路は,がんにおける全局的なRNAスプライシング異常によって活性化されます.
- STTは免疫経路を活性化することで,新しい抗腫瘍免疫戦略の可能性を秘めています.
関連する概念動画
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

